Table 1 Background characteristics of the patients in this study
Baseline variables | All patients (n = 704) | Cancer cases (n = 38) | Cancer-free cases (n = 666) | p-value | |||
|---|---|---|---|---|---|---|---|
Median | IQR | Median | IQR | Median | IQR | ||
Age at registration, years | 44 | 34–55 | 50 | 42–65 | 44 | 34–55 | < 0.001* |
Age at SLE diagnosis, years | 30 | 21–41 | 31 | 25–50 | 30 | 21–41 | 0.078 |
Sex (% female) | 625 (88.8) | 34 (89.5) | 591 (88.7) | 1.000 | |||
SELENA-SLEDAI at SLE diagnosis | 14 | (9–20) | 13 | (9–22) | 14 | (9–19) | 0.980 |
SDI (without cancer) at registration | 0 | 0–0 | 1 | 0–1 | 0 | 0–0 | < 0.001* |
Comorbidity of lupus nephritis | 248 (36.0) | 16 (42.1) | 232 (35.7) | 0.487 | |||
Comorbidity of diabetes mellitus | 44 (7.0) | 6 (16.7) | 38 (6.4) | 0.033* | |||
Comorbidity of hypertension | 231 (32.8) | 13 (34.2) | 218 (32.7) | 0.860 | |||
Comorbidity of hyperlipidemia | 174 (24.8) | 11 (30.2) | 161 (24.4) | 0.408 | |||
Habitual drinking | 67 (15.2) | 7 (30.4) | 60 (14.4) | 0.065 | |||
Smoking history | 246 (35.1) | 25 (65.8) | 221 (33.4) | < 0.001* | |||
History of cervical cancer vaccination | 35 (5.2) | 0 (0.0) | 35 (5.5) | 0.250 | |||
Maximum glucocorticoid dose (mg/day) | 40 | 30–60 | 50 | 30–60 | 40 | 30–60 | 0.157 |
IVCY | 165 (23.5) | 8 (21.6) | 157 (23.6) | 1.000 | |||
CNIs | 91 (12.9) | 6 (15.8) | 85 (12.8) | 0.617 | |||
MMF | 44 (6.3) | 3 (7.9) | 41 (6.2) | 0.725 | |||
MZR | 106 (15.1) | 4 (10.5) | 102 (15.3) | 0.639 | |||
MTX | 25 (3.6) | 1 (2.6) | 24 (3.6) | 1.000 | |||
AZP | 112 (15.9) | 6 (15.8) | 106 (15.9) | 1.000 | |||
HCQ | 193 (27.5) | 7 (18.4) | 186 (28.0) | 0.262 | |||